Flortaucipir (tau) PET in LGI1 antibody encephalitis

Ann Clin Transl Neurol. 2021 Feb;8(2):491-497. doi: 10.1002/acn3.51297. Epub 2021 Jan 7.

Abstract

The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18 F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients (3 men; median age, 67 [37-88] years). Imaging findings in cases were compared with those observed in age- and gender-similar cognitively normal individuals (n = 124) and individuals with early-symptomatic Alzheimer disease (n = 11). Elevated [18 F]flortaucipir retention was observed in the two LGI1 patients with hippocampal atrophy and persistent cognitive impairment, including one with autopsy-confirmed Alzheimer disease. Tau neuropathology may associate with cognitive complaints and hippocampal atrophy in recovering LGI1 patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / pathology
  • Autoantibodies
  • Brain / diagnostic imaging*
  • Brain / pathology*
  • Carbolines / metabolism*
  • Cognitive Dysfunction
  • Encephalitis / immunology*
  • Encephalitis / pathology
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins / immunology*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuroimaging / methods*
  • Positron-Emission Tomography / methods*
  • tau Proteins / immunology*
  • tau Proteins / metabolism

Substances

  • Autoantibodies
  • Carbolines
  • Intracellular Signaling Peptides and Proteins
  • LGI1 protein, human
  • tau Proteins
  • 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole